NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Phase 2

Active, not recruiting

Conditions: Localized Prostate Carcinoma
Prostate Adenocarcinoma
Stage I Prostate Cancer AJCC v8
Stage II Prostate Cancer AJCC v8

Interventions: Drug: Apalutamide
Procedure: Biospecimen Collection
Other: Quality-of-Life Assessment

First Posted Date: 2020-08-28

Last Posted Date: 2025-01-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT04530552

Locations: 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States

and more 2 locations

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Phase 3

Recruiting

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Biological: Blinatumomab
Drug: Dasatinib
Drug: Cyclophosphamide
Procedure: Echocardiography Test
Drug: Cytarabine
Procedure: Electrocardiography
Procedure: Lumbar Puncture
Drug: Dexamethasone
Procedure: Multigated Acquisition Scan
Drug: Doxorubicin Hydrochloride
Drug: Ponatinib Hydrochloride
Drug: Prednisone
Drug: Mesna
Drug: Methotrexate
Drug: Vincristine Sulfate

First Posted Date: 2020-08-28

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 348

Registration Number: NCT04530565

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 203 locations

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Metastatic Pancreatic Adenocarcinoma
Unresectable Malignant Solid Neoplasm
Unresectable Neuroendocrine Carcinoma
Unresectable Pancreatic Adenocarcinoma
Stage IV Lung Cancer AJCC v8
Metastatic Lung Small Cell Carcinoma
Metastatic Neuroendocrine Carcinoma
Stage III Lung Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Elimusertib
Drug: Irinotecan Hydrochloride
Procedure: Magnetic Resonance Imaging
Drug: Topotecan Hydrochloride

First Posted Date: 2020-08-17

Last Posted Date: 2025-03-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT04514497

Locations: 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 20 locations

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Phase 1

Active, not recruiting

Conditions: Advanced Lung Small Cell Carcinoma
Advanced Kaposi Sarcoma
Advanced Lung Non-Small Cell Carcinoma
Advanced Hepatocellular Carcinoma
Advanced Melanoma
Advanced Ovarian Carcinoma
Advanced Prostate Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Clinical Stage III Cutaneous Melanoma AJCC v8
Metastatic Urothelial Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2020-08-17

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT04514484

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Montefiore Medical Center-Einstein Campus, Bronx, New York, United States

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Phase 2

Terminated

Conditions: Urothelial Cancer

Interventions: Drug: Bintrafusp alfa (M7824)

First Posted Date: 2020-08-06

Last Posted Date: 2022-03-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT04501094

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Phase 1

Withdrawn

Conditions: Lynch Syndrome
Recurrent Lymphoma
Recurrent Neuroblastoma
Refractory Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Recurrent Primary Central Nervous System Neoplasm
Refractory Primary Central Nervous System Neoplasm
Constitutional Mismatch Repair Deficiency Syndrome
Refractory Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Procedure: Biospecimen Collection
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2020-08-05

Last Posted Date: 2022-09-10

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04500548

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Early Phase 1

Suspended

Conditions: Endometrial Serous Adenocarcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Resection
Drug: Triapine

First Posted Date: 2020-07-31

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT04494113

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 4 locations

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Breast Carcinoma
Advanced Cervical Carcinoma
Advanced Esophageal Carcinoma
Advanced Gastric Carcinoma
Advanced Head and Neck Carcinoma
Advanced Lung Non-Small Cell Carcinoma
Advanced Lung Small Cell Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Advanced Bile Duct Carcinoma

Interventions: Drug: Cisplatin
Drug: Elimusertib
Drug: Gemcitabine Hydrochloride

First Posted Date: 2020-07-30

Last Posted Date: 2025-02-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT04491942

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States

and more 5 locations